BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 17501758)

  • 1. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Núnez M; Camino N; Ramos B; Berdún MA; Barreiro P; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Martín-Carbonero L; Romero M; García-Samaniego J; Soriano V
    Antivir Ther; 2005; 10(5):657-62. PubMed ID: 16152759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
    Núñez M; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de Los Santos I; San Joaquín I; Echeverría S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola JM; Romero M; García-Samaniego J; Soriano V;
    AIDS Res Hum Retroviruses; 2007 Aug; 23(8):972-82. PubMed ID: 17725413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
    Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
    HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
    Núñez M; Mariño A; Miralles C; Berdún MA; Sola J; Hernandez-Burruezo JJ; Galindo MJ; Barreiro P; Martin-Carbonero L; Soriano V
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):439-44. PubMed ID: 17468669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.